J&J, Alkermes, AbbVie, others set to benefit from expanding schizophrenia drug market

Oct. 22, 2022 4:00 PM ETJohnson & Johnson (JNJ), ABBV, TEVA, ALKSOTSKF, OTSKY, KRTX, CERE, MDCLF, HLUBF, HLBBFBy: Jonathan Block, SA News Editor8 Comments

Mental health conditions, schizophrenia diagnosis and treatment with antipsychotic medication and psychotherapy.

Olivier Le Moal/iStock via Getty Images

An increase in the patient population combined with new therapies in development means that the schizophrenia drug market will soar to $13B in 2031 from $9B in 2021, according to consulting and analytical

Recommended For You

Comments (8)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.